The Genomic Landscape of Intrinsic and Acquired Resistance to Cyclin-Dependent Kinase 4/6 Inhibitors in Patients with Hormone Receptor-Positive Metastatic Breast Cancer

激素受体阳性转移性乳腺癌患者对细胞周期蛋白依赖性激酶 4/6 抑制剂的内在和获得性耐药的基因组图谱

阅读：9

作者：Seth A Wander #, Ofir Cohen #, Xueqian Gong #, Gabriela N Johnson, Jorge E Buendia-Buendia, Maxwell R Lloyd, Dewey Kim, Flora Luo, Pingping Mao, Karla Helvie, Kailey J Kowalski, Utthara Nayar, Adrienne G Waks, Stephen H Parsons, Ricardo Martinez, Lacey M Litchfield, Xiang S Ye, Chunping Yu, Valerie

期刊：

Cancer Discovery

影响因子：

29.700

时间：

2020

起止号：

2020 Aug;10(8):1174-1193.

doi：

10.1158/2159-8290.CD-19-1390

方法学：

HTRF、IP、WB

靶点：

Bub1b

研究方向：

肿瘤

疾病类型：

乳腺癌

细胞类型：

其它细胞

Significance

We identified eight distinct mechanisms of resistance to CDK4/6i present in 66% of resistant tumors profiled. Most of these have a therapeutic strategy to overcome or prevent resistance in these tumors. Taken together, these findings have critical implications related to the potential utility of precision-based approaches to overcome resistance in many patients with HR+ metastatic breast cancer.This article is highlighted in the In This Issue feature, p. 1079.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用；引用内容仅为补充信息，不代表本站立场。

2、若认为本页面引用内容涉及侵权，请及时与本站联系，我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容，需注明“来源：[生知库]”并获得授权；使用引用内容的，需自行联系原作者获得许可。

4、投稿及合作请联系：info@biocloudy.com。